Scholarlink

<p>Whether lamotrigine (LTG) is associated with ventricular tachycardia (VT) in bipolar disorder (BPD), partial seizures (PSZ) and generalized tonic-clonic seizures (GTSZ) with and without structural heart disease (SHD) remains controversial leading to a real-world comparative cohort observational study. A retrospective observational comparative safety study was performed using a large healthcare claims database of adult participants, analyzing the risk of VT incidence. Patients diagnosed with BPD, PSZ or GTSZ where free from supraventricular (SVT) or VT during the 6-month baseline period. Exposure to LTG versus commonly prescribed alternative agents was the CTR. One-year cumulative VT incidence was calculated for GTSZ, PSZ and BPD using Kaplan-Meier estimator adjusted for baseline characteristics. The analytic cohort included 153,852 LTG and 213,593 CTR for BPD, 10,275 LTG and 24,971 CTR for PSZ, and 5,860 LTG and 17,506 CTR for GTSZ. The 1-year VT cumulative incidence from LTG or CTR free from was 0.79% vs. 0.68% in BPD, 0.76% vs. 0.58% in PSZ, and 0.93% vs. 0.40% in GTSZ cohorts, The adjusted HR [95% CI] estimates were 1.326 [1.122–1.568, <i>p</i> &lt; 0.01], 1.403 [0.920–2.138, <i>p</i> = 0.11], and 1.180 [0.607–2.295, <i>p</i> = 0.63]. In adult participants with BPD, LTG has a statistically significant association to increase VT risk compared to commonly prescribed alternatives.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of ventricular arrhythmias with lamotrigine: an observational cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Sodam Kim,
  • Landon Welch,
  • Bertha De Los Santos,
  • Przemysław B. Radwański,
  • Mark A. Munger,
  • Kibum Kim

摘要

Whether lamotrigine (LTG) is associated with ventricular tachycardia (VT) in bipolar disorder (BPD), partial seizures (PSZ) and generalized tonic-clonic seizures (GTSZ) with and without structural heart disease (SHD) remains controversial leading to a real-world comparative cohort observational study. A retrospective observational comparative safety study was performed using a large healthcare claims database of adult participants, analyzing the risk of VT incidence. Patients diagnosed with BPD, PSZ or GTSZ where free from supraventricular (SVT) or VT during the 6-month baseline period. Exposure to LTG versus commonly prescribed alternative agents was the CTR. One-year cumulative VT incidence was calculated for GTSZ, PSZ and BPD using Kaplan-Meier estimator adjusted for baseline characteristics. The analytic cohort included 153,852 LTG and 213,593 CTR for BPD, 10,275 LTG and 24,971 CTR for PSZ, and 5,860 LTG and 17,506 CTR for GTSZ. The 1-year VT cumulative incidence from LTG or CTR free from was 0.79% vs. 0.68% in BPD, 0.76% vs. 0.58% in PSZ, and 0.93% vs. 0.40% in GTSZ cohorts, The adjusted HR [95% CI] estimates were 1.326 [1.122–1.568, p < 0.01], 1.403 [0.920–2.138, p = 0.11], and 1.180 [0.607–2.295, p = 0.63]. In adult participants with BPD, LTG has a statistically significant association to increase VT risk compared to commonly prescribed alternatives.